India Equity Analytics 19-Jul-19

# Colgate Palmolive (India)Ltd.<sup>19-Jul-19</sup> Result Update

Industry	Cons. Staples
Bloomberg	CLGT IN
BSE CODE	500830

RATING	HOLD
СМР	1203
Price Target	1269
Potential Upside	5%

Rating Change	<b></b>
Estimate Change	Î
Target Change	Î

# Stock Info

52wk Range H/L	1365/1020
Mkt Capital (Rs Cr)	32719
Free float (%)	49%
Avg. Vol 1M (,000)	402
No. of Shares (Crs)	27
Promoters Pledged %	NA

# Tepid rural growth impacted the overall volume growth

Narnolia™

### 1QFY20 Result update

- COLPAL's 1QFY20 numbers remained in line with our estimates, revenue grew by 4.2% YoY to Rs. 1085 cr. backed by domestic volume growth 4% YoY while pricing growth remained flat.
- The Company's volume growth remained subdued on account of slowdown in demand due to lower than expected growth in rural markets although management sees this trend as temporary and expect a pickup over the coming quarters.
- The Company re-launched Colgate Strong Teeth total with new Amino Shakti while launched Colgate Zig Zag Neem at a price point of Rs. 35 and also launched limited special edition range of toothbrushes under its Colgate Super flexi Viraat Pack.
- □ Gross margin deteriorated by 5 bps to 65.86% YoY (vs. expect. of 65.2% YoY) led by increase in COGS while EBITDA margin improved by 59 bps to 27.6% YoY (vs. expect. of 26% YoY) led by reduction in other expense by 131 bps(may have been impacted by adoption of Ind AS lease) while employee expense and Ad & P expense increased by 50 bps and 17 bps.
- The Company's PAT stood at Rs. 169 cr. (vs. expect. of Rs. 166 cr.) impacted by lower Top line with PAT de-growth of 11% YoY while PAT margin declined by 261 bps YoY to 15.6%due to impact of exceptional item of Rs 34 cr in previous quarter.

### View and Valuation

COLPAL has reported numbers inline with our estimates, sales were up by 4% to Rs 1085 cr(vs expec. Rs 1085 cr) while PAT declined by 11% to Rs 169 cr( vs expec. Rs 166 cr) impacted by subdued rural growth. Overall volume grew by 4% (vs expec. 4%). Management sees this rural slowdown as temporary blip, expects recovery soon. Now company is focusing more on their core business with new launches in natural space. The company has increased its investment in A&P and ramping up their distribution which is in our opinion is prudent strategy. This will drive growth for the company going ahead. Waning up of competitive intensity from Patanjali augurs well for the company. We continue to value COLPAL at 43x of FY20e eps and maintain HOLD rating with the target price 1269.

# Key Risks to our rating and target

Delayed revival in rural growth.

Higher Ad & Promotion expense due to brand building activities.

KEY FINANCIAL/VALUATIONS	FY17	FY18	FY19	FY20E	FY21E
Net Sales	3982	4188	4462	4774	5188
EBITDA	944	1112	1236	1348	1420
EBIT	810	956	1077	1149	1232
PAT	577	673	776	803	865
EPS (Rs)	21	25	29	30	32
EPS growth (%)	-1%	17%	15%	4%	8%
ROE (%)	45%	44%	54%	53%	54%
ROCE (%)	64%	63%	71%	72%	73%
BV	47	56	53	56	59
Р/В (Х)	20	19	22	21	20
P/E (x)	43	43	41	41	38

# The views expressed above accurately reflect the personal views of the authors about the subject companies and its(their) securities. The authors have not and will not receive any compensation for providing a specific recommendation or view. Narnolia Financial Advisors Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

# **Research Analyst**

RAJEEV ANAND rajeev.anand@narnolia.com +91-22-62701229

# 1QFY20 Results In line with Expectation

Financials	1QFY19	2QFY19	3QFY19	4QFY19	1QFY20	YoY %	QoQ%	FY18	FY19	YoY %
Net Sales	1,041	1,168	1,099	1,154	1,085	4.2%	-6.0%	4,188	4,462	6.6%
Other Income	9	9	8	12	15	65.6%	26.9%	39	38	-3.0%
COGS	355	412	383	409	370	4.3%	-9.4%	1,490	1,559	4.6%
Gross Margin	66%	65%	65%	65%	66%	-0.1%	1.3%	64%	65%	0.7%
Emp. Cost	75	76	71	73	83	11.4%	13.6%	306	296	-3.3%
Other Exp.	186	212	205	205	180	-3.4%	-12.1%	1,280	1,372	7.2%
EBITDA	282	330	314	310	300	6.5%	-3.4%	1,112	1,236	11.1%
EBITDA Mar.	27%	28%	29%	27%	28%	0.6%	0.7%	27%	28%	1.1%
Depreciation	39	40	41	39	50	26.6%	26.7%	157	159	1.7%
EBIT	242	290	274	271	250	3.2%	-7.8%	956	1,077	12.7%
Interest	-	-	-	3	2	-	-7.6%	-	3	-
PBT	251	298	282	281	263	4.6%	-6.3%	995	1,112	12%
Exceptional	(34)	-	-	4	-	-100%	-	12	(31)	-362%
Тах	96	102	90	79	94	-2.4%	18.1%	310	367	19%
PAT	190	196	192	198	169	-10.8%	-14.4%	673	776	15%
PAT Margin	18%	17%	17%	17%	16%	-2.6%	-1.5%	16%	17%	1.3%

### Slowdown in rural impacted volumes


In 1QFY20, COLPAL volumes remained impacted due to more than expected slowdown in demand from rural. Despite of the above prevailing conditions the company maintained its volume growth of 4% YoY (vs. expect. of 3.5% YoY).Further, the company will continue investing in advertising and brand building activities in order to strengthen its brands and will also continue increasing its direct reach (increased its direct coverage by 30% as of Oct-18). The Company's Toothpaste and Toothbrush volume market share as of Mar-19 stood at 52% and 48.2% respectively. The company expects the trend of rural slowdown to be temporary and expects revival in rural demand in the coming quarters.

#### Reduction in other expenses resulted into EBITDA Margin expansion

COLPAL gross margin declined by 5 bps to 65.86% YoY on account of increase in COGS which may be due to higher promotions made by the company while EBITDA margin improved by 59 bps to 27.6% YoY led by decline in other expense by 131 bps to 16.6% YoY while employee expense and Ad & P expense increased by 50 bps and 17 bps. The company will continue investing in advertising and brand building activities which in turn will drive volumes.


## **Exhibit: Domestic Volume Growth**

Volumes remained impacted on account of moderation in demand due to slowdown in rural growth.




## **Exhibit: Sales and Sales Growth**

Sales growth remained subdued led by lower volumes due to rural slowdown.




#### **Exhibit: Gross and EBITDA Margin**

GROSSM. remained impacted on account of higher COGS while EBITDAM. improved led by reduction in other expense.




#### Exhibit: Ad&P,Employee and other expenses

EBITDAM. Improvement led by decline in other exp. while employee and Ad exp. increased by 50 bps and 17 bps.




#### Exhibit: PAT and PAT Growth

PAT posted a de-growth of 11% YoY to Rs. 169 cr. with a PAT margin of 15.6% YoY in 1QFY20.



#### **Exhibit: Return on Equity**

Return on Equity(ROE) is expected to be at 53% and 54% in FY20e and FY21e respectively.



# **Financial Details**

# **Balance Sheet**

Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
Share Capital	14	14	27	27	27	27	27	27
Reserves	586	757	1,004	1,247	1,497	1,420	1,500	1,586
Networth	600	770	1,031	1,274	1,525	1,447	1,527	1,614
Debt	-	-	-	-	-	78	78	78
Other Non Current Liab	52	65	28	53	55	50	50	50
Total Capital Employed	600	770	1,031	1,274	1,525	1,524	1,605	1,691
Net Fixed Assets (incl CWIP)	697	923	1,087	1,275	1,304	1,390	1,325	1,272
Non Current Investments	37	30	31	31	31	31	31	31
Other Non Current Assets	89	59	25	54	39	28	28	28
Non Current Assets	823	1,012	1,228	1,468	1,503	1,616	1,552	1,499
Inventory	226	252	292	293	227	249	266	289
Debtors	55	70	102	130	201	210	224	244
Cash & Bank	285	254	193	199	305	378	571	748
Other Current Assets	104	113	77	69	80	31	33	36
Current Assets	670	690	775	856	1,061	1,010	1,224	1,457
Creditors	498	514	552	601	614	613	656	713
Provisions	70	66	49	56	60	64	68	74
Other Current Liabilities	273	286	136	136	102	103	111	120
Curr Liabilities	842	867	943	995	983	1,051	1,121	1,214
Net Current Assets	(172)	(177)	(168)	(140)	78	(41)	103	243
Total Assets	1,493	1,702	2,003	2,323	2,564	2,626	2,777	2,956

## **Income Statement**

Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
Revenue from Operation	3,579	3,982	3,868	3,982	4,188	4,462	4,774	5,188
Change (%)	13%	11%	-3%	3%	5%	7%	7%	9%
EBITDA	664	822	939	944	1,112	1,236	1,348	1,420
Change (%)	1%	24%	14%	1%	18%	11%	9%	5%
Margin (%)	19%	21%	24%	24%	27%	28%	28%	27%
Depr & Amor.	51	75	111	133	157	159	199	188
EBIT	613	747	827	810	956	1,077	1,149	1,232
Int. & other fin. Cost	-	-	-	-	-	3	7	7
Other Income	50	33	40	41	39	38	56	56
EBT	664	780	867	851	995	1,112	1,198	1,281
Exp Item	64	-	(31)	-	(12)	31	-	-
Тах	188	221	254	274	310	367	396	416
Minority Int & P/L share of Ass.	-	-	-	-	-	-	-	-
Reported PAT	540	559	581	577	673	776	803	865
Adjusted PAT	494	559	603	577	681	755	803	865
Change (%)	-1%	13%	8%	-4%	18%	11%	6%	8%
Margin(%)	14%	14%	16%	15%	16%	17%	17%	17%

# **Financial Details**

# Key Ratios

Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
ROE	90%	73%	56%	45%	44%	54%	53%	54%
ROCE	102%	97%	80%	64%	63%	71%	72%	73%
Asset Turnover	2	2	2	2	2	2	2	2
Debtor Days	6	6	10	12	18	17	17	17
Inv Days	23	23	28	27	20	20	20	20
Payable Days	51	47	52	55	54	50	50	50
Int Coverage						431	164	176
P/E	17	21	47	43	43	41	41	38
Price / Book Value	15	15	26	20	19	22	21	20
EV/EBITDA	13	14	29	26	26	26	24	23
FCF per Share	10	25	15	13	18	26	33	35
Div Yield	4%	3%	1%	1%	1%	2%	2%	2%

# **Cash Flow Statement**

Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
РВТ	664	780	867	851	995	1,143	1,198	1,281
(inc)/Dec in Working Capital	(37)	5	16	31	(89)	28	28	37
Non Cash Op Exp	44	85	107	130	157	143	199	188
Int Paid (+)	-	-	-	-	-	3	7	7
Tax Paid	(178)	(206)	(252)	(301)	(347)	(367)	(396)	(416)
others	(35)	(27)	(17)	(23)	(21)	-	-	-
CF from Op. Activities	457	638	689	688	694	921	1,036	1,097
(inc)/Dec in FA & CWIP	(324)	(300)	(273)	(321)	(209)	(204)	(135)	(135)
Free Cashflow	134	338	416	367	485	717	902	962
(Pur)/Sale of Inv	10	-	7	-	-	0	-	-
others	133	28	29	(21)	2	-	-	-
CF from Inv. Activities	(180)	(272)	(237)	(342)	(207)	(204)	(135)	(135)
inc/(dec) in NW	-	-	(16)	(14)	(9)	-	-	-
inc/(dec) in Debt								
Int. Paid	-	-	-	-	-	(3)	(7)	(7)
Div Paid (inc tax)	(422)	(385)	(376)	(327)	(371)	(850)	(723)	(779)
others	-	-	-	-	-	75	(7)	(7)
CF from Fin. Activities	(422)	(385)	(391)	(341)	(380)	(775)	(730)	(786)
Inc(Dec) in Cash	(145)	(18)	61	5	107	(57)	172	176
Add: Opening Balance	296	151	133	193	199	456	399	571
Closing Balance	151	132	193	199	305	399	571	748

Narnolia Financial Advisors Ltd. is a SEBI registered Research Analyst having SEBI Registration No. INH300006500. The Company/Analyst (s) does/do not have any holding in the stocks discussed but these stocks may have been recommended to clients in the past. Clients of Narnolia Financial Advisors Ltd. may be holding aforesaid stocks.

The stocks recommended are based on our analysis which is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed.

Disclosures: Narnolia Financial Advisors Ltd. (NFAL) (FormerlyMicrosec Capital Ltd.) is a SEBI Registered Research Analyst having registration no. INH300006500. NFALis engaged in the business of providing Stock Broking, Depository Participant, Merchant Banking, Portfolio Management & distribution of various financial products. Details of associate entities of NFAL is available on the website at www.narnolia.com

No penalties have been levied on NFAL by any Regulatory/Statutory authority, NFAL, it's associates. Research Analyst or their relative may have financial interest in the subject company. NFAL and/or its associates and/or Research Analyst may have beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report. NFAL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of NFAL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. Research Analyst may have served as director/officer. etc. in the subject company in the last 12 month period. NFAL and/or its associates may have received compensation from the subject company in the past 12 months. In the last 12 months period ending on the last day of the month immediately preceding the date of publication of this research report, NFAL or any of its associates may have: a) managed or co-managed public offering of securities from subject company of this research report, b) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d) Subject Company may have been a client of NFAL or its associates during 12 months preceding the date of distribution of the research report. NFAL and it's associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. NFAL and / or its affiliates may do and seek to do business including Investment Banking with companies covered in the research reports. As a result, the recipients of this report should be aware that NFAL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific Merchant Banking, Investment Banking or Brokerage service transactions. Research Analyst's views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of NFAL or its associates maintains arm's length distance with Research Team as all the activities are segregated from NFAL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### **Disclosure of Interest Statement-**

Analyst's ownership of the stocks mentioned in the Repor	:	NIL

A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>.

Correspondence Office Address: Arch Waterfront, 5th Floor, Block GP, Saltlake, Sector 5, Kolkata 700 091; Tel No.: 033-40541700; www.narnolia.com.

Registered Office Address: Marble Arch, Office 201, 2nd Floor, 236B, AJC Bose Road, Kolkata 700 020; Tel No.: 033-4050 1500; www.narnolia.com

Compliance Officer: Manish Kr Agarwal, Email Id: mkagarwal@narnolia.com, Contact No.:033-40541700.

Registration details of Company: Narnolia Financial Advisors Ltd. (NFAL): SEBI Stock Broker Registration: INZ000166737 (NSE/BSE/MSEI); NSDL/CDSL: IN-DP-380-2018; Research Analyst: INH300006500, Merchant Banking: (Registration No.: INM000010791), PMS: (Registration No.: INP000002304), AMFI Registered Mutual Fund distributor: ARN 3087

Registration Details of Group entities: G. Raj & Company Consultants Ltd (G RAJ)-BSE Broker INZ260010731; NSDL DP: IN-DP-NSDL-371-2014 || Narnolia Commerze Limited (Formerly Microsec Commerze Ltd.)-MCX/NCDEX Commodities Broker: INZ000051636 || NarnoliaVelox Advisory Ltd.- SEBI Registered PMS: INP000005109 || Eastwind Capital Advisors Pvt Ltd. (EASTWIND)-SEBI Registered Investment Adviser: INA300005439 || Narnolia Insurance Brokers Limited (Formerly Microsec Insurance Brokers Ltd.)-IRDA Licensed Direct Insurance Broker (Life & Non-Life) Certificate No. 134, License No. DB046/02 || Narnolia Securities Ltd. (NSL)-AMFI Registered Mutual Fund distributor: ARN 20558, PFRDA NPS POP: 27092018 || Narnolia Capital Advisors Pvt. Ltd. - RBI Registered MBFC:B.05.02568.

#### Disclaimer:

This report has been prepared by Narnolia Financial Advisors Ltd. (NFAL)and is meant for sole use by the recipient and not for public circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of NFAL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment grade securities - involve substantial risk and are not suitable for all investors. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his/her/its own advisors to determine the merits and risks of such an investment. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NFAL will not treat recipien

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NFAL & its group companies to registration or licensing requirements within such jurisdictions.